Johnson & Johnson COVID-19 Vaccine Roll-out to Resume in Europe Following European Medicines Agency (EMA) ReviewEMA Confirms Overall Benefit-Risk Profile Remains Positive
NEW BRUNSWICK, N.J., April 20, 2021 – Johnson & Johnson (NYSE: JNJ) (the Company) today announced that the European Medicines Agency’s (EMA) Pharmacovigilance Risk Assessment Committee (PRAC) has provided updated guidance for use of the Company’s COVID-19 vaccine and confirmed the overall benefit-risk profile remains positive. The guidance follows PRAC review of a small number of cases of a very rare adverse event involving blood clots in combination with low platelet counts that can occur within approximately one to three weeks following injection with the Company’s COVID-19 vaccine. As a resul...
Source: Johnson and Johnson - April 20, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news

No, vaccine side effects don ’t tell you how well your immune system will protect you
Is there any link between what you can notice after a vaccine and what ’s happening on the cellular level inside your body? Robert Finberg, a physician who specializes in infectious diseases and immunology at the Medical School at the University of Massachusetts, explains how this perception doesn’t match the reality of how vaccines work. (Source: bizjournals.com Health Care News Headlines)
Source: bizjournals.com Health Care News Headlines - April 20, 2021 Category: Health Management Authors: Robert Finberg Source Type: news

New safer blood test is close to 100 per cent accurate at spotting nut allergies 
A trial by doctors at Guy's and St Thomas' Hospital in London has found that the test - called the basophil activation test (BAT) - is close to 100 per cent accurate at spotting nut allergies. (Source: the Mail online | Health)
Source: the Mail online | Health - April 20, 2021 Category: Consumer Health News Source Type: news

U.S. FDA Approves ALK's Ragwitek (Short Ragweed Pollen Allergen Extract) Tablet for Sublingual Use as Immunotherapy for Children and Adolescents With Short Ragweed Pollen-Induced Allergic Rhinitis With or Without Conjunctivitis
ROUND ROCK, Texas, April 19, 2021 /PRNewswire/ -- ALK (ALKB: DC / OMX: ALK B / AKABY / AKBLF), a global, research-driven pharmaceutical company that focuses on the diagnosis and treatment of allergies, announced that the U.S. Food and Drug... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - April 19, 2021 Category: Drugs & Pharmacology Source Type: news

Janssen Provides Update on Phase 3 ACIS Study in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with ERLEADA ® (apalutamide) and ZYTIGA® (abiraterone acetate) Plus Prednisone Combination
RARITAN, N.J., April 19, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that regulatory submissions based on the Phase 3 ACIS study, which evaluated the combination of ERLEADA® (apalutamide) and ZYTIGA® (abiraterone acetate) plus prednisone in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC), will not be pursued. As presented at the American Society of Clinical Oncology’s Genitourinary (ASCO GU) Cancers Symposium in February 2021, the ACIS study met its primary endpoint of radiographic progression-free survival (rPFS); ho...
Source: Johnson and Johnson - April 19, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Is It Allergies or COVID? Expert Shows How to Tell the Difference
MONDAY, April 19, 2021 -- Seasonal allergies are striking this year at the worst possible time, with the United States in the midst of a fourth wave of the global COVID-19 pandemic. You've got an itchy nose and watery eyes. Or maybe you've got a... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - April 19, 2021 Category: General Medicine Source Type: news

Warmer Climate, More Pollen, Worse Allergies: How to Fight Back
Title: Warmer Climate, More Pollen, Worse Allergies: How to Fight BackCategory: Health NewsCreated: 4/18/2021 12:00:00 AMLast Editorial Review: 4/19/2021 12:00:00 AM (Source: MedicineNet Allergies General)
Source: MedicineNet Allergies General - April 19, 2021 Category: Allergy & Immunology Source Type: news

Is It Allergies or COVID? How to Tell the Difference
Title: Is It Allergies or COVID? How to Tell the DifferenceCategory: Health NewsCreated: 4/19/2021 12:00:00 AMLast Editorial Review: 4/19/2021 12:00:00 AM (Source: MedicineNet Allergies General)
Source: MedicineNet Allergies General - April 19, 2021 Category: Allergy & Immunology Source Type: news

Updated advice for safe COVID-19 vaccination in people with high-risk allergy histories
(Massachusetts General Hospital) Experts have narrowed the group of individuals with prior allergies who should see an allergist before receiving a COVID-19 vaccine. Allergy evaluation with skin testing prior to COVID-19 vaccination is rarely needed. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - April 19, 2021 Category: Infectious Diseases Source Type: news

Warmer Climate, More Pollen, Worse Allergies: How to Fight Back
SUNDAY, April 18, 2021 -- Climate change has made North America's pollen season longer and more severe, but there are ways to reduce your allergy misery, according to the American College of Allergy, Asthma and Immunology (ACAAI). The best way to... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - April 18, 2021 Category: General Medicine Source Type: news

Add India to UK travel ban list to stop Covid variant, urges scientist
Indian coronavirus variant has potential to ‘scupper’ lockdown easing, says professor of immunologyCoronavirus – latest updatesSee all our coronavirus coverageIndia should be placed on the UK ’s “red list” for travel after the discovery of a new coronavirus variant, according to a leading scientist.Prof Danny Altmann, from Imperial College London, said it was “mystifying” and “confounding” that those flying in from the country were not required to stay in a hotel.Continue reading... (Source: Guardian Unlimited Science)
Source: Guardian Unlimited Science - April 17, 2021 Category: Science Authors: Nadeem Badshah Tags: Coronavirus Science Travel India Immunology Infectious diseases UK news Source Type: news

Will You Need a Booster Shot of the COVID-19 Vaccine?
When the first COVID-19 vaccines from Pfizer-BioNTech and Moderna were authorized by the U.S. Food and Drug Administration in December 2020, most people breathed a sigh of relief since both shots were shown to be between 94% and 95% effective in protecting from COVID-19 symptoms. But public health experts warned that nobody really knew how long the protection would last, since the longest clinical trials in people only went to a few months. Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases (NIAID) and the chief medical advisor to President Joe Biden, suggested that additional booster ...
Source: TIME: Health - April 16, 2021 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized COVID-19 Source Type: news

New data for Roche ’s OCREVUS (ocrelizumab) reinforce significant benefit on slowing disease progression in relapsing and primary progressive multiple sclerosis
Basel, 16 April 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced new OCREVUS ® (ocrelizumab) analyses supporting its significant benefit on disease progression in early-stage relapsing-remitting multiple sclerosis (RRMS) and primary progressive MS (PPMS) as well as demonstrating high persistence and strong adherence to twice-yearly (six-monthly) dosing. These data are being presented virtually at the 73rd American Academy of Neurology (AAN) Annual Meeting from 17–22 April 2021. OCREVUS is the number one prescribed MS medication in the U.S. for patients starting a new treatment, and more than 200,000 peop...
Source: Roche Investor Update - April 16, 2021 Category: Pharmaceuticals Source Type: news

New data for Roche ’s OCREVUS (ocrelizumab) reinforce significant benefit on slowing disease progression in relapsing and primary progressive multiple sclerosis
Basel, 16 April 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced new OCREVUS ® (ocrelizumab) analyses supporting its significant benefit on disease progression in early-stage relapsing-remitting multiple sclerosis (RRMS) and primary progressive MS (PPMS) as well as demonstrating high persistence and strong adherence to twice-yearly (six-monthly) dosing. These data are being presented virtually at the 73rd American Academy of Neurology (AAN) Annual Meeting from 17–22 April 2021. OCREVUS is the number one prescribed MS medication in the U.S. for patients starting a new treatment, and more than 200,000 peop...
Source: Roche Media News - April 16, 2021 Category: Pharmaceuticals Source Type: news

Experimental antiviral for COVID-19 effective in hamster study
(NIH/National Institute of Allergy and Infectious Diseases) The experimental antiviral drug MK-4482 significantly decreased levels of virus and disease damage in the lungs of hamsters treated for SARS-CoV-2 infection, according to a new study from NIH scientists. MK-4482, delivered orally, is now in human clinical trials. Remdesivir, an antiviral drug already approved by the U.S. Food and Drug Administration for use against COVID-19, must be provided intravenously, making its use primarily limited to clinical settings. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - April 16, 2021 Category: Infectious Diseases Source Type: news

Asthma Exacerbations, ED Admissions Decreased During Lockdown
Nonpharmaceutical interventions to reduce COVID - 19 associated with reduction in admissions for COPD, asthma (Source: Pulmonary Medicine News - Doctors Lounge)
Source: Pulmonary Medicine News - Doctors Lounge - April 15, 2021 Category: Respiratory Medicine Tags: Family Medicine, Internal Medicine, Allergy, Emergency Medicine, Pharmacy, Pulmonology, Journal, Source Type: news

Milk Is Overtaking Nuts as Top Food Allergy Threat Milk Is Overtaking Nuts as Top Food Allergy Threat
Cow's milk is in so many foods that it can be difficult to avoid yet it is the most common food allergy in young children.Medscape Medical News (Source: Medscape General Surgery Headlines)
Source: Medscape General Surgery Headlines - April 15, 2021 Category: Surgery Tags: Allergy & Clinical Immunology News Source Type: news

The Pandemic Remade Every Corner of Society. Now It ’s the Climate’s Turn
On her third day as the Secretary of Housing and Urban Development, Marcia Fudge phoned the White House. She had taken over an agency with a role to play addressing a range of crises as the lack of affordable housing in U.S. cities has left hundreds of thousands homeless and millions more in financial straits. She connected with Joe Biden’s climate team. Fudge and Gina McCarthy, Biden’s national climate adviser, talked about addressing climate change and the affordable-­housing shortage at the same time. Three weeks later, the Administration announced plans to provide for more than 1 million resilient and e...
Source: TIME: Science - April 15, 2021 Category: Science Authors: Justin Worland Tags: Uncategorized climate change Cover Story feature Magazine TIME 2030 Source Type: news

AHA News: 5 Things to Know This Earth Day About How the Environment Affects Health
Title: AHA News: 5 Things to Know This Earth Day About How the Environment Affects HealthCategory: Health NewsCreated: 4/14/2021 12:00:00 AMLast Editorial Review: 4/15/2021 12:00:00 AM (Source: MedicineNet Allergies General)
Source: MedicineNet Allergies General - April 15, 2021 Category: Allergy & Immunology Source Type: news

UGA to establish national NIH-funded center to fight flu
(University of Georgia) The National Institutes of Health has awarded the University of Georgia a contract to establish the Center for Influenza Disease and Emergence Research (CIDER). The contract will provide $1 million in first-year funding and is expected to be supported by the National Institute of Allergy and Infectious Diseases (NIAID), part of NIH, for seven years and up to approximately $92 million. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - April 15, 2021 Category: Biology Source Type: news

Nothing Could Make Her Body Stop Itching. Would It Ever End?
It felt like the itch was coming from somehow under her skin. The cause ended up being even deeper. (Source: NYT Health)
Source: NYT Health - April 14, 2021 Category: Consumer Health News Authors: Lisa Sanders, M.D. Tags: Allergies Tests (Medical) Itching Skin Lymph Nodes and Lymphatic System Eczema Source Type: news

NIAID funds new influenza research network
(NIH/National Institute of Allergy and Infectious Diseases) The National Institute of Allergy and Infectious Diseases has established a network of research sites to study the natural history, transmission and pathogenesis of influenza and provide an international research infrastructure to address influenza outbreaks. The program, called the Centers of Excellence for Influenza Research and Response (CEIRR), is expected to be supported for seven years by NIAID contracts to five institutions. Funding for the first year of the contracts will total approximately $24 million. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - April 14, 2021 Category: Infectious Diseases Source Type: news

Shape-shifting Ebola virus protein exploits human RNA to change shape
(La Jolla Institute for Immunology) The new study shows how one of Ebola virus's key proteins, VP40, uses molecular triggers in the human cell to transform itself into different tools for different jobs. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - April 14, 2021 Category: Infectious Diseases Source Type: news

Las Vegas family awarded $29.5M in allergic reaction case
A jury has awarded $29.5 million to the family of a woman who was left brain damaged after being treated for a severe allergic reaction by an ambulance service in Las Vegas in 2013 (Source: ABC News: Health)
Source: ABC News: Health - April 13, 2021 Category: Consumer Health News Tags: Health Source Type: news

Anaphylaxis Case After mRNA Vaccination Traced to Polyethylene Glycol Allergy Anaphylaxis Case After mRNA Vaccination Traced to Polyethylene Glycol Allergy
An undiagnosed polyethylene glycol allergy was at the root of at least one anaphylaxis case associated with an mRNA-based COVID-19 vaccine, a UK report suggests.Reuters Health Information (Source: Medscape Emergency Medicine Headlines)
Source: Medscape Emergency Medicine Headlines - April 13, 2021 Category: Emergency Medicine Tags: Infectious Diseases News Source Type: news

Flagship-founded immunology startup bags $189M from Softbank, others
Repertoire Immune Medicines, the immunology startup formed last year by the merging of two Flagship Pioneering-founded companies, has secured $189 million as it looks to "decode" cancer, autoimmune disorders and infectious diseases, in that order. (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - April 13, 2021 Category: Biotechnology Authors: Rowan Walrath Source Type: news

FDA Approves Xolair (omalizumab) Prefilled Syringe for Self-Injection Across All Indications
●  Xolair for self-injection offers healthcare providers and appropriate patients another administration option for more flexibility in managing their treatmentBasel, 13 April 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) has approved the company ’s supplemental Biologics License Application for Xolair® (omalizumab) prefilled syringe for self-injection across all approved U.S. indications.1 Xolair is the only FDA-approved biologic designed to target and block immunoglobulin E (IgE) for the treatment of moderate to severe persistent allergic ...
Source: Roche Media News - April 13, 2021 Category: Pharmaceuticals Source Type: news

FDA Approves Xolair (omalizumab) Prefilled Syringe for Self-Injection Across All Indications
●  Xolair for self-injection offers healthcare providers and appropriate patients another administration option for more flexibility in managing their treatmentBasel, 13 April 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) has approved the company ’s supplemental Biologics License Application for Xolair® (omalizumab) prefilled syringe for self-injection across all approved U.S. indications.1 Xolair is the only FDA-approved biologic designed to target and block immunoglobulin E (IgE) for the treatment of moderate to severe persistent allergic ...
Source: Roche Investor Update - April 13, 2021 Category: Pharmaceuticals Source Type: news

NIH experts discuss post-acute COVID-19
(NIH/National Institute of Allergy and Infectious Diseases) Many people who have COVID-19 make a full recovery and return to their baseline state of health; however, some people have symptoms or other sequelae weeks or months after initial SARS-CoV-2 infection. These symptoms were the subject of the " Workshop on Post-acute Sequelae of COVID-19 " hosted on Dec. 2 and 4, 2020, by the National Institute of Allergy and Infectious Diseases (NIAID), in collaboration with other institutes and centers of the NIH. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - April 13, 2021 Category: Infectious Diseases Source Type: news

NIH trial of anti-CD14 antibody to treat COVID-19 respiratory disease begins
(NIH/National Institute of Allergy and Infectious Diseases) A clinical trial testing the safety and efficacy of an investigational monoclonal antibody for treating people who are hospitalized with respiratory disease and low blood oxygen due to infection with SARS-CoV-2, the virus that causes COVID-19, has begun. The Phase 2 trial, called the COVID-19 anti-CD14 Treatment Trial (CaTT), is sponsored and funded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - April 13, 2021 Category: International Medicine & Public Health Source Type: news

Had Facial Fillers? What You Need to Know About COVID Vaccines
MONDAY, April 12, 2021 -- Once you've landed that coveted coronavirus vaccine appointment, you'll likely have to fill out a form on your medical history and whether you're allergic to any of the vaccine's ingredients. But there could be another... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - April 12, 2021 Category: General Medicine Source Type: news

US begins study of allergic reactions from mRNA coronavirus vaccines, proving covid vaccine long-term safety studies have never been conducted
(Natural News) The U.S. will start a study focusing on the allergic reactions triggered by mRNA Wuhan coronavirus (COVID-19) vaccines. The trial, conducted by the National Institute of Allergy and Infectious Diseases (NIAID), will examine if people with a history of allergies have a higher chance of experiencing reactions beyond the injection site. It will also look... (Source: NaturalNews.com)
Source: NaturalNews.com - April 12, 2021 Category: Consumer Health News Source Type: news

Phase III prevention trial showed subcutaneous administration of investigational antibody cocktail casirivimab and imdevimab reduced risk of symptomatic COVID-19 infections by 81%
Basel, 12 April 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today confirmed positive results from the phase III REGN-COV 2069 trial assessing the ability of the investigational antibody cocktail casirivimab and imdevimab to reduce the risk and burden of COVID-19 infection among household contacts of SARS-CoV-2 infected individuals. The trial, which was jointly run with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), met its primary and key secondary endpoints. It showed that the subcutaneous administration of casirivimab and imdevimab reduced the risk of sym...
Source: Roche Media News - April 12, 2021 Category: Pharmaceuticals Source Type: news

Phase III prevention trial showed subcutaneous administration of investigational antibody cocktail casirivimab and imdevimab reduced risk of symptomatic COVID-19 infections by 81%
Basel, 12 April 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today confirmed positive results from the phase III REGN-COV 2069 trial assessing the ability of the investigational antibody cocktail casirivimab and imdevimab to reduce the risk and burden of COVID-19 infection among household contacts of SARS-CoV-2 infected individuals. The trial, which was jointly run with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), met its primary and key secondary endpoints. It showed that the subcutaneous administration of casirivimab and imdevimab reduced the risk of sym...
Source: Roche Investor Update - April 12, 2021 Category: Pharmaceuticals Source Type: news

Mayo Clinic Minute: How to get spring allergy relief
Springtime brings warmer temperatures and blooming trees. But, for close to 1 in 3 Americans, it also brings annoying seasonal allergies. Dr. Alexei Gonzalez Estrada, a Mayo Clinic allergy specialist, says there are steps you can take to protect yourself. Watch: The Mayo Clinic Minute https://youtu.be/5WigboWy0q8 Journalists: Broadcast-quality video (0:59) is in the downloads at [...] (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - April 12, 2021 Category: Databases & Libraries Source Type: news

Las Vegas family awarded $29.5M in allergic reaction case
A jury has awarded $29.5 million to the family of a woman who was left brain damaged after being treated for a severe allergic reaction by an ambulance service in Las Vegas in 2013 (Source: ABC News: Health)
Source: ABC News: Health - April 11, 2021 Category: Consumer Health News Tags: Health Source Type: news

The impact of chemotherapy on immune cells in the tumor microenvironment
(Queen Mary University of London) Research from Queen Mary University of London has revealed novel insights into the effects of chemotherapy on the tumour microenvironment (TME). The study, published today in Cancer Immunology Research, a journal of the American Association for Cancer Research, found that chemotherapy enhances the anti-tumour actions of immune cells within the TME and their ability to support immune responses against cancer. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - April 10, 2021 Category: Cancer & Oncology Source Type: news

Dietary Advice Poor for Mothers Breastfeeding Infants With Food Allergies
FRIDAY, April 9, 2021 -- Physician recommendations to mothers providing breast milk to children with immunoglobulin (Ig)E-mediated food allergies are inconsistent, according to a study recently published in the Annals of Allergy, Asthma&... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - April 9, 2021 Category: Pharmaceuticals Source Type: news

Parallels in Sepsis and COVID-19 Conditions: Implications for Managing Severe COVID-19, Frontiers in immunology
Sepsis is a life-threatening systemic illness attributed to a dysregulated host response to infection. Sepsis is a global burden killing ~11 million persons annually. In December 2019, a novel pneumonia condition termed coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), emerged and has resulted in more than 1,535,982 deaths globally as of 8 th December 2020. These two conditions share many pathophysiological and clinical features. Notably, both sepsis and COVID-19 patients experience consumptive thrombocytopenia, haemolytic anaemia, vascular microthrombosis, multi-o...
Source: Current Awareness Service for Health (CASH) - April 9, 2021 Category: Consumer Health News Source Type: news

Former Pfizer scientist warns that governments and pharmaceutical companies will continue to deceive and enslave people before killing them off
(Natural News) Dr. Michael Yeadon, Pfizer’s former Vice President and Chief Scientist for Allergy and Respiratory Disease, warns that governments will continue to deceive populations and lie to people about infectious disease diagnosis, transmission and risk. The government’s perpetual deceit and authoritarianism during the covid-19 scandal has been used to control, discriminate, oppress, harass, divide... (Source: NaturalNews.com)
Source: NaturalNews.com - April 9, 2021 Category: Consumer Health News Source Type: news

Interleukin-33 involved in immunity to Sars-CoV-2
(Max Planck Institute of Immunobiology and Epigenetics) Early in the Corona pandemic, a team of immunologists from the Max Planck Institute of Immunobiology and Epigenetics in Freiburg and physicians from the University of Freiburg Medical Center joined forces to learn more about immunity in people recovering from Corona infections. The study revealed a yet unknown involvement of Interleukin 33, an important alarm-signal, when immune cells get exposed to Sars-CoV-2 for a second time. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - April 9, 2021 Category: International Medicine & Public Health Source Type: news

NIH Starts Trial Looking at Rare Allergic Reactions to COVID-19 Vaccines
THURSDAY, April 8, 2021 -- A new clinical trial will investigate whether people who are highly allergic or have a mast cell disorder are at higher risk for a sudden allergic reaction to the Moderna or Pfizer COVID-19 vaccines. " The public... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - April 8, 2021 Category: Pharmaceuticals Source Type: news

NIH Looking Into Rare Allergic Reactions to COVID Vaccines
Researchers will look at the biological mechanism causing the reactions and whether there is a way to predict who is at most risk. (Source: WebMD Health)
Source: WebMD Health - April 8, 2021 Category: Consumer Health News Source Type: news

Using Multicolor Flow Cytometry for COVID-19 Research
Designing multicolor flow cytometry panels to characterize immunological changes observed in COVID-19 patients. (Source: The Scientist)
Source: The Scientist - April 8, 2021 Category: Science Tags: The Marketplace Source Type: news

Dose-Response Analysis Could Improve Peanut Allergy Labeling
THURSDAY, April 8, 2021 -- Estimating the dose-response distribution for peanut allergen in the U.S. population could help improve food labeling guidelines for the management of peanut allergies, according to a study published online March 12 in... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - April 8, 2021 Category: Pharmaceuticals Source Type: news

NIH Starts Trial Looking at Rare Allergic Reactions to COVID Vaccines
THURSDAY, April 8, 2021 -- A new clinical trial will investigate whether people who are highly allergic or have what's known as a mast cell disorder are at higher risk for a sudden allergic reaction to the Moderna or Pfizer COVID-19 vaccines. " The... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - April 8, 2021 Category: General Medicine Source Type: news

Ex-Purdue exec's year-old immunology startup secures $100M
Ventus Therapeutics, the immunology startup launched last May and headed up by former Purdue chief medical officer Marcelo Bigal, has raised another $100 million to bring its drugs into the clinic by the end of 2022. (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - April 8, 2021 Category: Pharmaceuticals Authors: Rowan Walrath Source Type: news

NIH experts call for accelerated research to address concurrent HIV and COVID-19 pandemics
(NIH/National Institute of Allergy and Infectious Diseases) The COVID-19 pandemic is affecting people with or at risk for HIV by interfering with HIV treatment and prevention services, and by threatening individual health. An effective response to these dual pandemics requires collaboration to accelerate basic and clinical research, and implementation science to introduce evidence-based strategies into real-world settings. This message comes from a review article co-authored by NIAID director Anthony S. Fauci, M.D., and colleagues published in the Journal of Infectious Diseases. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - April 8, 2021 Category: Infectious Diseases Source Type: news

Former Pfizer VP: 'Your government is lying to you in a way that could lead to your death.'
(Natural News) Dr. Michael Yeadon, Pfizer’s former Vice President and Chief Scientist for Allergy & Respiratory who spent 32 years in the industry leading new medicines research and retired from the pharmaceutical giant with “the most senior research position” in his field, spoke with LifeSiteNews. (Article by Patrick Delaney republished from LifeSiteNews.com) He addressed the “demonstrably false” propaganda... (Source: NaturalNews.com)
Source: NaturalNews.com - April 8, 2021 Category: Consumer Health News Source Type: news

Comment on "Tumor-initiating cells establish an IL-33-TGF-{beta} niche signaling loop to promote cancer progression"
Taniguchi et al. (Research Articles, 17 July 2020, p. 269) claim that the cytokine interleukin-33 induces accumulation of tumor-associated macrophages expressing the immunoglobulin E receptor FcRI. Although these findings hold great therapeutic promise, we provide evidence that the anti-FcRI antibody used in this study is not specific for FcRI on macrophages, which raises concerns about the validity of some of the conclusions. (Source: ScienceNOW)
Source: ScienceNOW - April 8, 2021 Category: Science Authors: Kamphuis, J. B. J., Worrall, W. P. M., Stackowicz, J., Mougel, A., Maure, E., Conde, E., Bruhns, P., Guilleminault, L., Gaudenzio, N., Chen, J., Gentek, R., Reber, L. L. Tags: Immunology, Medicine, Diseases t-comment Source Type: news